drugset / Trial / NCT03244930

Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation

NCT03244930

Phase 2 Unknown 20 enrolled Hospital Universitario Dr. Jose E. Gonzalez
NaSingle-groupOpen-labelTreatment

Summary

Plerixafor, is added to mobilizing chemotherapy and G-CSF to overcome poor stem cell mobilization. We want to demonstrate that half of the commonly prescribed dose can be safely administered once as a single dose in first attempt leading to apheresis yields of \>2 x 106 CD34+ cells/kg body weight.

Timeline

Start
2017-05-10
Primary completion
2018-05-10
Completion
2018-06-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Plerixafor Small molecule 0.12 mg/kg Subcutaneous